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was maintained as long as the effect metric used for Cox 
regression had a linear correlation with the true effect 
metric of at least 0.50. The conclusions held if the trial 
cohort consisted of an expected high benefit population (22% 
reduced sample size), but the effect was even stronger if the 
cohort was a population with modest expected benefit (31% 
reduced sample size). 
 
 
 
Conclusion: We have demonstrated that the required patient 
sample size for randomized trials in radiation oncology may 
be considerably reduced by taking heterogeneous dose-effect 
into account. Dual planning provides support for the 
statistical outcome modelling that increases trial power even 
if the dose-response model is moderately misspecified. The 
outcome of a trial in the example studied would be a 
randomized measure of 'benefit per Gy ∆MLD' with confidence 
interval. 
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Purpose or Objective: Gastrointestinal (GI) toxicity is a side-
effect induced by whole pelvis intensity modulated 
radiotherapy (WP-IMRT), affecting importantly patients’ 
quality of life. The aim of this study was to identify 
predictors of diarrhea in a cohort of chemo-naÏf patients 
treated with WP-IMRT after prostatectomy. 
 
Material and Methods: The Inflammatory Bowel Disease 
questionnaire (IBDQ) was used to assess the degree of GI 
symptoms after WP-IMRT, investigating 4 distinct areas: 
bowel and systemic symptoms, emotional and social 
functions. This study focused on the most clinically relevant 
item 5 relative to the bowel domain, in order to evaluate the 
frequency of liquid defecation. Patient-reported scores at 
baseline, at RT mid-point and end, and every 3 months after 
RT end were prospectively collected . The responses are 
scored on a 7-point scale where 7 corresponds to the best 
function and 1 to the worst. Clinical/dosimetric data in 115 
patients treated with adjuvant (n=65) or salvage (n=50) WPRT 
in a single Institute were available (static field IMRT:19; 
VMAT:55; Tomotherapy:41). Dose–volume histograms (DVHs) 
for intestinal loops and sigmoid colon were calculated. The 
25th percentile of the score variation between baseline and 
half/end RT was considered as end-point (∆ -IBDQ5≤-3). 
Associations between diarrhea and clinical/DVH parameters 
were assessed by logistic uni- and backward multi-variable 
analyses. A previously introduced method based on DVH 
differences between patients with/without diarrhea toxicity 
was used to select the most discriminative DVH parameters. 
 
Results: No significant correlation emerged for sigmoid 
colon, then the analysis was focused on intestinal loops. 
Patients without basal score and with ∆ -IBDQ5≤-3 were 
excluded from the analysis: 23/77 pts showed acute GI 
toxicity. At univariate analysis, volumes receiving 5 to 40Gy 
(V5-V40) were correlated with ∆ -IBDQ5≤- 3 (p<0.03). 
Multivariate analysis confirmed a leading role of dosimetric 
variables, while no significant correlation for clinical 
parameters was found. Best cut-off values (assessed by ROC) 
discriminating patients with/without ∆ -IBDQ5≤-3 were: 
V20<250cc, V30<150cc and V40<90cc. The overall incidence 
equal to 10% and 50% resulted for the group of patients with 
DVH parameters lower/higher than thresholds, respectively 
(p=0.0028, OR=4.9, AUC=0.68).  
 
 
 
Conclusion: Low-medium IMRT doses to intestinal loops were 
correlated to diarrhea symptom at half/end of RT. This study 
proposed new dose volume constraints, that may be used to 
prevent much radiation-induced GI morbidity. 
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Purpose or Objective: MRI-based focal tumour boosting is 
currently under clinical investigation for prostate cancer 
patients, e.g. in the FLAME trial. These highly conformal, 
focal dose distributions can be difficult to achieve with 
photons, depending on the size and location of the boost 
volume (i.e. proximity to critical organs at risk). Selected 
patients might therefore be candidates for proton therapy. In 
previous work we have established an MRI-based tumour 
control probability (TCP) model. Combined with published 
rectum and bladder normal tissue complication probability 
(NTCP) models we have in this study explored the use of 
biological (TCP and NTCP) models to identify prostate cancer 
patients that might be suitable candidates for proton therapy 
if treated according to FLAME-like trial protocols. 
 
Material and Methods: CT scans of seven patients from a 
prospective trial in our institution were used for planning. To 
obtain realistic boost geometries, MRI-based index tumours 
from a different cohort were used (matched on prostate 
volume), propagated with rigid registration on the prostate 
volume. VMAT plans (Eclipse, Varian Medical Systems) with 
and without a boost to the index lesion (95 Gy / 35 fx) were 
created; both plans delivered a conventional dose (77 Gy / 35 
